VRTX
Status-Quo-PlayerVertex Pharmaceuticals
$440.05
+0.86%
as of 13 Apr
Power Core
Power Core in one sentence: Vertex's moat is the compounding molecular complexity of the CFTR protein itself, which has defeated every external challenger's drug design efforts for over a decade, transforming a patent-protected franchise into a biology-protected monopoly.
Direction of Movement
Upward, Compounding Through Franchise Depth and Pipeline Breadth
ROC 200
-2.7%
VRTX
Vertex Pharmaceuticals
$440.05
+0.86%
as of 13 Apr
DCF Fair Value: $418.37
Market data unavailable
Company Profile
Vertex Pharmaceuticals Incorporated is a leading biotechnology company founded in 1989 and headquartered in Boston, Massachusetts. It specializes in the discovery, development, and commercialization of transformative therapies, with a primary focus on cystic fibrosis (CF), a life-threatening genetic disease. The company markets a portfolio of CF treatments, including TRIKAFTA/KAFTRIO for patients aged 2 and older with at least one F508del mutation, ALYFTREK for those 6 years and older, SYMDEKO/SYMKEVI and ORKAMBI for patients 6 years and 1 year or older respectively, and KALYDECO for infants as young as 1 month with specific CF mutations. Vertex Pharmaceuticals Incorporated plays a pivotal role in the pharmaceuticals and biotech sector by addressing unmet needs in rare diseases through innovative small-molecule drugs. Its pipeline extends beyond CF into areas like acute and neuropathic pain, with candidates such as VX-548 advancing toward regulatory approval. With trailing twelve-month revenue of approximately $9.72 billion and a market capitalization around $86-101 billion, the company demonstrates significant financial strength and global market presence across multiple exchanges.